Society guidelines library

Evidence-based management of incidental pulmonary nodules on CT: solid, subsolid, ground-glass, and multiple. Size and risk stratify every follow-up interval.

Detection and risk stratification of clinically significant prostate cancer on multiparametric MRI. T2W, DWI, and DCE assessment by zone.

Standardized diagnosis and reporting of HCC in at-risk patients. Major features, ancillary features, and LR-1 through LR-5, LR-M, LR-TIV categories.

Breast imaging reporting and data system. Assessment categories 0–6 across MG, US, and MRI with lexicon for masses, calcifications, and enhancement.

Lung cancer screening reporting and data system. Category-based management of screening LDCT with growth, morphology, and modifier rules (S, C).

Point-based risk stratification of thyroid nodules on US. TR1–TR5 classification and size cutoffs for FNA and follow-up.

Malignancy risk stratification of cystic renal masses using wall thickness, septations, calcifications, and enhancement.

Response evaluation criteria in solid tumors. Target vs non-target lesions, new lesions, and CR/PR/SD/PD categorization.

IPMN and MCN surveillance. Worrisome features and high-risk stigmata drive endoscopic ultrasound vs surgical resection.

Primary staging and restaging of rectal adenocarcinoma. MRF, EMVI, and mrTRG assessment for neoadjuvant response.

Size, washout thresholds, and follow-up cadence for the incidental adrenal mass.

Standardized ultrasound classification of adnexal lesions with clear risk categories O-RADS 1–5.

ACR White Papers on incidental findings across liver, kidney, adrenal, pancreas, thyroid, adnexa, and lung.

FIGO 2018 stage-driven MRI protocol. Parametrial invasion, tumor size, and nodal status guide chemoradiation vs surgery.

Immune-modified RECIST for immunotherapy trials. iUPD (unconfirmed) and iCPD (confirmed) account for pseudoprogression.

Post-locoregional treatment response of HCC: LR-TR Nonviable, Equivocal, Viable — applies to ablation, TACE, TARE.

Solid renal mass characterization and nephrometry scoring for surgical planning.

Myometrial invasion depth, cervical stromal extension, and molecular subtypes in FIGO 2023 staging.

Diffuse glioma classification by IDH/1p19q status and RANO 2.0 response criteria including pseudoprogression rules.

Malignancy risk stratification of adnexal lesions on MRI. Categories 1–5 based on solid tissue, DCE curve, and DWI.

Peritoneal disease burden, nodal spread, and PCI scoring for cytoreductive planning.

Muscle invasion risk on MRI using structured T2W, DWI, and DCE scores (VI-RADS 1–5).